(S (NP (NP (NNP Hydroxyurea)) (-LRB- -LRB-) (NP (NNP HU)) (-RRB- -RRB-)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG alleviating) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NML (NNP Sickle) (NNP Cell) (NNP Anemia)) (NN disease)))))))))))))) (. .))
(S (SBAR (IN While) (S (NP (NNP Hydroxyurea)) (VP (VBZ reduces) (NP (NP (DT the) (NNS complications)) (VP (VBN associated) (PP (IN with) (NP (NP (NN Sickle) (NN Cell) (NN Anemia)) (PP (IN in) (NP (DT some) (NNS patients)))))))))) (, ,) (NP (NNS others)) (VP (VBP do) (RB not) (VP (VB benefit) (PP (IN from) (NP (NP (DT this) (NN drug)) (CC and) (NP (NN experience) (JJ deleterious) (NNS effects)))) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ is) (ADVP (RB also)) (NP (DT a) (JJ chemotherapeutic) (NN agent))))))) (. .))
(S (ADVP (RB Therefore)) (, ,) (SBAR (SINV (PP (TO to) (NP (WP whom))) (, ,) (MD should) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP HU)))) (VP (VB be) (VP (VBN considered) (PP (IN as) (NP (DT a) (JJ viable) (NN option))))))) (, ,) (VP (VBZ is) (NP (NP (DT the) (JJ main) (NN question)) (VP (VBN asked) (PP (IN by) (NP (DT the) (JJ responsible) (NN physician)))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP address) (NP (DT this) (NN question)) (PP (IN by) (NP (NP (VBG developing) (NN modeling) (NNS techniques)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB predict) (NP (NP (DT a) (NN patient) (POS 's)) (NN response)) (PP (IN to) (NP (NNP HU)))))))))) (CC and) (VP (ADVP (RB therefore)) (VBP spare) (NP (NP (DT the) (JJ non-responsive) (NNS patients)) (PP (IN from) (NP (NP (DT the) (JJ unnecessary) (NNS effects)) (PP (IN of) (NP (NNP HU)))))) (PP (IN on) (NP (NP (DT the) (NNS values)) (PP (IN of) (NP (NP (CD 22) (NNS parameters)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN obtained) (PP (IN from) (NP (NP (NN blood) (NNS samples)) (PP (IN in) (NP (CD 122) (NNS patients)))))))))))))))) (. .))
(S (S (VP (VBG Using) (NP (DT this) (NNS data)))) (, ,) (NP (PRP we)) (VP (VBD developed) (NP (NP (NP (NNP Deep) (NNP Artificial)) (NP (JJ Neural) (NN Network) (NNS models))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB predict) (PP (IN with) (NP (NP (QP (CD 92.6) (NN %)) (NN accuracy)) (, ,) (NP (NP (DT the) (JJ final) (NN HbF) (NN value)) (PP (IN of) (NP (DT a) (NN subject)))))) (PP (IN after) (S (VP (VBG undergoing) (NP (NN HU) (NN therapy))))))))))) (. .))
(S (NP (PRP$ Our) (JJ current) (NNS studies)) (VP (VBP are) (VP (VBG focussing) (PP (IN on) (S (VP (VBG forecasting) (NP (NP (NP (DT a) (NN patient) (POS 's)) (NN HbF) (NN response)) (, ,) (NP-TMP (CD 30) (NNS days)) (PP (RB ahead) (IN of) (NP (NN time))))))))) (. .))
